Elena Yu. Morgunova

Elena Yu. Morgunova

Auto-generated profile, based on publicly available information

Elena Yu. Morgunova

National Research Center for Epidemiology and Microbiology named after honorary academician N.F. Gamaleya

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NBNataliya Bondareva
Nataliya Bondareva
ASAnna Sheremet
Anna Sheremet
EMElena Y. Morgunova
Elena Y. Morgunova
IKIrina R. Khisaeva
Irina R. Khisaeva
APAlisa Parfenova
Alisa Parfenova
Ludmila BoinovichLudmila Boinovich
Ludmila Boinovich
The global spread of multidrug-resistant (MDR) hospital-acquired pathogens is a serious problem for healthcare units. The challenge of the spreading of nosocomial infections, also known as hospital-acquired pathogens, including Pseudomonas aeruginosa, must be addressed not only by developing effective drugs, but also by improving preventive measures in hospitals, such as passive bactericidal coatings deposited onto the touch surfaces. In this paper, we studied the antibacterial activity of superhydrophilic and superhydrophobic copper surfaces against the P. aeruginosa strain PA103 and its four different polyresistant clinical isolates with MDR. To fabricate superhydrophilic and superhydrophobic coatings, we subjected the copper surfaces to laser processing with further chemosorption of fluorooxysilane to get a superhydrophobic substrate. The antibacterial activity of superhydrophilic and superhydrophobic copper surfaces was shown, with respect to both the collection strain PA103 and polyresistant clinical isolates of P. aeruginosa, and the evolution of the decontamination of a bacterial suspension is presented and discussed. The presented results indicate the promising potential of the exploitation of superhydrophilic coatings in the manufacture of contact surfaces for healthcare units, where the risk of infection spread and contamination by hospital-acquired pathogens is extremely high.

Verified
Journal Article
Open access
PDF file
OVOlga L. Voronina
Olga L. Voronina
MKMarina Kunda
Marina Kunda
NRNatalia Ryzhova
Natalia Ryzhova
EAEkaterina Aksenova
Ekaterina Aksenova
EGElizaveta R. Goncharova
Elizaveta R. Goncharova
NZNailya Zigangirova
Nailya Zigangirova
Extraintestinal pathogenic Escherichia coli causes community-acquired and nosocomial pneumonia and poses a risk of infection, especially for patients with impaired lung function, such individuals with cystic fibrosis (CF). When chronic infection develops, eradication of the pathogen is difficult even with aggressive antibacterial therapy and targeted CF treatment. A new agent, Fluorthiazinone (CL-55), an inhibitor of bacterial virulence, was registered in Russia in 2024. The aim of our study was to characterize the genomes of E. coli ST648 isolated from long-term-infected CF patients, describe virulence factors, and investigate the effect of CL-55 on two CF isolates in vitro. Comparison of the genomes of hypermucoviscous isolates showed that, in the presence of a large number of core genes, the isolates have adaptive differences both in their chromosomes and the composition and genes of their plasmidomes. Both isolates formed mature biofilms on an abiotic surface and were able to survive and proliferate inside macrophages. CL-55 in in vitro experiments was effective in suppressing E. coli ST648 in both the aggregate and intracellular states, allowing us to propose the use of Fluorthiazinone as a combinative therapy to facilitate eradication of pathogenic microorganisms in the respiratory tract in patients with CF.

31 October 2025 in Journal of microbiology, epidemiology and immunobiology
Verified
Journal Article
Open access
PDF file
LKLydiya N. Kapotina
Lydiya N. Kapotina
EMElena Yu. Morgunova
Elena Yu. Morgunova
SNStanislava A. Nelyubina
Stanislava A. Nelyubina
EFElena D. Fedina
Elena D. Fedina
EKEkaterina Koroleva
Ekaterina Koroleva
NZNailya Zigangirova
Nailya Zigangirova
The aim of this study was to investigate the effect of the innovative Russian antibacterial drug Fluorothiazinone, an inhibitor of the type III secretion system and flagellar function, on the virulence properties of urinary tract infection (UTI) pathogens. Materials and methods. Clinical isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa species were obtained from 4 patients with recurrent UTI. Cytotoxicity analysis was performed on HeLa cells using the CytoTox 96 kit. Bacterial flagellar motility was assessed in 0.25% agar by measuring the zone of motility. Biofilms were cultivated in 96-well plates and stained with crystal violet and Congo red. Biofilm structure was assessed by microscopy, and the bacterial biofilm and exopolysaccharide matrix were quantified by measuring the optical density of the dye bound to the biofilm. Intracellular development was studied in PC-3 cells by determining the number of intracellular bacteria using a cell lysate plating method and an immunochemical method involving staining the bacteria with specific antibodies. Results. The Fluorothiazinone antibacterial specifically inhibited the cytotoxicity and motility of E. coli and P. aeruginosa. For K. pneumoniae, susceptibility to Fluorothiazinone was observed, associated with the suppression of cytotoxicity. For all the isolates studied, inhibition of biofilm formation on an abiotic surface was demonstrated. For E. coli and K. pneumoniae, a significant decrease in intracellular replication within human prostate adenocarcinoma cells and suppression of intracellular bacterial community formation were observed. Conclusion. Fluorothiazinone disrupts mechanisms that contribute to pathogen persistence in the formation of chronic UTI, including biofilm formation on abiotic surfaces such as catheters, stents, and drains, and the formation of intracellular bacterial communities and dormant intracellular reservoirs.

4 August 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
OVOlga L. Voronina
Olga L. Voronina
MKMarina Kunda
Marina Kunda
NRNatalia Ryzhova
Natalia Ryzhova
EAEkaterina Aksenova
Ekaterina Aksenova
EGElizaveta R. Goncharova
Elizaveta R. Goncharova
NZNailya Zigangirova
Nailya Zigangirova
Extraintestinal pathogenic Escherichia coli causes community-acquired and nosocomial pneumonia, and poses a risk of infection, especially for patients with impaired lung function, such as patients with cystic fibrosis (CF). When chronic infection develops, eradication of the pathogen is difficult even with aggressive antibacterial therapy and targeted CF treatment. A new compound, Fluorthiazinone (CL-55), an inhibitor of bacterial virulence, was registered in Russia in 2024. The aim of our study was to characterize the genomes of E. coli ST648 isolated from long-term infected CF patients, describe AMR and virulence factors, and investigate the effect of CL-55 on CF isolates in vitro. Comparison of the genomes of hypermucoviscous isolates showed that, in the presence of a large number of core genes, the isolates have adaptive differences both in chromosome and in the composition and genes of the plasmidome. Both isolates formed mature biofilms on an abiotic surface and were able to survive and proliferate inside macrophages. CL-55 in in vitro experiments was effective in suppressing E. coli ST648 in both the aggregate and intracellular states, which allows us to propose the use of Fluorothiazinone as a combinative therapy to facilitate eradication of pathogenic microorganisms in the respiratory tract of patients with CF.